Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
A phase 3 trial of zanidatamab, capecitabine, futibatinib and ivosidenib in gallbladder cancer and other biliary tract cancers, run by UNICANCER, not yet recruiting.
Overview
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer is a phase 3, randomised interventional study registered as NCT07745296 by UNICANCER, with a registry enrolment figure of 990 participants, started 2027-01-02 and due to reach its primary completion in 2033-07-02. Interventions recorded: Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine, Capecitabine (Xeloda). Conditions listed: Biliary Tract Cancer (BTC). Gallbladder cancer is named in the registry entry: "2. Histologically-proven intrahepatic cholangiocarcinoma, perihilar or distal extrahepatic cholangiocarcinoma or gallbladder carcinoma (ampullary carcinoma is excluded)". No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAdjuvant Chemotherapy for BTC Based on 3D-PTA
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Capecitabine and the tag gallbladder-deep-dive.
- TrialLenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialPhase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialAdoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialAn Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Shares IDH inhibitors, Ivosidenib, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialTesting Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialCisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Capecitabine and the tag gallbladder-deep-dive.